Close Menu

NEW YORK (GenomeWeb) – JP Morgan has downgraded Genomic Health to Underweight from Neutral, citing a slower than expected coverage expansion for the company's prostate cancer test, and a "tepid" outlook for the company's core breast cancer testing business.

The investment bank also lowered the price target on Genomic Health's stock price to $25 from $28.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.